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Abstract
Background: Pitx2 (paired-like homeodomain 2 transcription factor) is crucial for heart development, but its role in heart
failure (HF) remains uncertain. The present study lays the groundwork implicating Pitx2 signalling in different modalities of
HF.
Methodology/Principal Findings: A variety of molecular, cell-based, biochemical, and immunochemical assays were used to
evaluate: (1) Pitx2c expression in the porcine model of diastolic HF (DHF) and in patients with systolic HF (SHF) due to
dilated and ischemic cardiomyopathy, and (2) molecular consequences of Pitx2c expression manipulation in cardiomyocytes
in vitro. In pigs, the expression of Pitx2c, physiologically downregulated in the postnatal heart, is significantly re-activated in
left ventricular (LV) failing myocardium which, in turn, is associated with increased expression of a restrictive set of Pitx2
target genes. Among these, Myf5 was identified as the top upregulated gene. In vitro, forced expression of Pitx2c in
cardiomyocytes, but not in skeletal myoblasts, activates Myf5 in dose-dependent manner. In addition, we demonstrate that
the level of Pitx2c is upregulated in the LV-myocardium of SHF patients.
Conclusions/Significance: The results provide previously unrecognized evidence that Pitx2c is similarly reactivated in
postnatal/adult heart at distinct HF phenotypes and suggest that Pitx2c is involved, directly or indirectly, in the regulation of
Myf5 expression in cardiomyocytes.
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Introduction
The Pitx2 homeobox transcription factor gene was originally
identified as the candidate gene for the human Axenfeld-Rieger’s
syndrome [1], which is characterized by severe eye, teeth,
craniofacial and umbilical abnormalities; less common features
include heart defects [2,3]. Shortly after its identification, Pitx2 was
found to play an important role in early development, as revealed
by the generation of constitutive knockout mouse models.
Consistent with Pitx2 expression patterns, homozygous disruption
of the mouse Pitx2 gene led to mid-embryonic lethality due to
defects in cardiac morphogenesis, in addition to severe abdominal
wall and other tissue malformations [4–7]. Subsequently, the study
of the Pitx2 gene has become the object of continued research
efforts aimed at identifying its role in the fetal, adult and diseased
myocardium (reviewed in [8–11]).
Selective Pitx2 deletion in the developing myocardium resulted
in delayed differentiation of ventricular (but not atrial) cardiomy-
ocytes, as development proceeded from embryonic to prenatal
stages. During postnatal development, these mutants displayed
dilatation and enlargement of right heart chambers and
asymmetric hypertrophy of the interventricular septum associated
with severely impaired ventricular systolic function [12]. Cham-
ber-specific inactivation of Pitx2 within atrial myocardium led to
dilatation of both the left (LA) and right atrium (RA), in the
absence of significant defects in ventricular chambers of mutant
foetuses. However, after birth the mutants displayed a maladaptive
remodelling of both atria and ventricles, associated with electro-
physiological dysfunction, preferentially in the LA [13]. The atrial
conduction system is particularly sensitive to Pitx2 gene dose
because mice heterozygous for Pitx2 deficiency did not display
altered cardiac morphology and contractile function in any of the
heart chambers, but under electrical stimulation showed atrial
arrhythmias [14,15].
Three Pitx2 transcript variants (Pitx2a, Pitx2b, and Pitx2c) have
been identified in mammals, Pitx2c being the predominant or the
only transcript detected in the adult mouse and human heart [13–
17]. Of note, Pitx2c is differentially expressed across the cardiac
chambers with maximal expression in the LA [15]. Pitx2c
expression in the mouse LA is downregulated from fetal to
postnatal stages [14]. The roles played by Pitx2 within the four-
chambered postnatal heart are poorly understood, even though its
PLOS ONE | www.plosone.org 1 March 2014 | Volume 9 | Issue 3 | e90561
requirement is unquestioned. Conditional mouse mutants, in
which Pitx2 expression in atrial myocardium was turned off at
birth, developed atrial ultrastructural remodelling and sinus node
dysfunction [18]. Pitx2 plays a pivotal role restricting pacemaker
activity in the developing myocardium by repressing a nodal gene
program and activating the working myocardium gene program
[14,19,20]. Two groups independently found that Pitx2c expres-
sion is downregulated both in LA and in RA of patients with atrial
fibrillation (AF), suggesting that Pitx2c dysfunction could be
causatively linked to AF pathophysiology [13,15]. Although using
different in-vivo and in-vitro approaches, both groups provided
congruent evidence that the reduction of Pitx2c expression in the
adult atrial myocardium promotes its susceptibility to AF. These
results are well in line with recent findings which suggest that
Pitx2c loss-of-function mutations play a role in the genesis of the so-
called ‘‘lone’’ AF in patients with structurally normal atria [21].
This study uncovers a novel, previously unrecognized link
between heart failure (HF) and activation of the Pitx2 gene in
failing myocardium. To address this issue, we examined Pitx2c
expression in left ventricular (LV) myocardium in the porcine
model of diastolic HF (DHF) with preserved LV-ejection fraction.
The expression of Pitx2c, physiologically downregulated in the
postnatal heart, is significantly re-activated in failing myocardium
which, in turn, is associated with increased expression of a
restrictive set of Pitx2 target genes. Among these, Myf5 was
identified as the top upregulated gene. In vitro, forced expression of
Pitx2c in cardiomyocytes, but not in skeletal myoblasts, activates
Myf5 in dose-dependent manner. In addition, we demonstrate that
the level of Pitx2c is upregulated in the LV-myocardium at systolic
HF with severe reduced LV-ejection fraction in patients. Our
present study provides the initial framework for analyzing putative
contribution of Pitx2c re-activation in failing myocardium to the
overall progression of HF, possibly through the involvement of
Pitx2c in regulation of myogenic regulatory factor genes.
Materials and Methods
Heart failure porcine samples
Experimental procedures were carried out in accordance with
the European Commission Directive 86/609/EEC on the
protection of animals used for experimental and other scientific
purposes, and all protocols were approved by the Animal Care
and Use Ethical Committee of the University of La Corun˜a, Spain
(approval Nu:CE 012/2012). Newborn and early neonatal ‘‘Large
White’’ piglets were obtained from a local commercial breeder (La
Corun˜a, Spain), maintained in a conventional Nu¨rtinger nursery
system for days 6 after birth, randomized in two groups, and
assigned to receive a single intravenous injection of isotonic PBS
(phosphate-buffered saline) or 1.5–2.0 mg/kg of doxorubicin (Dox;
Sigma, Madrid, Spain) [22,23]. Untreated control group consisted
of six non-injected piglets. On day 24 after injection (i.e., on day
30 after birth), hemodynamic parameters (surface ECG, blood
pressure, heart rhythm, cardiac output, and extravascular lung
water) were monitored in closed-chest piglets, whereas the
measurements of LV end-systolic and end-diastolic pressure were
performed in open-chest piglets as described [24,25]. Dox-injected
piglets displayed diastolic dysfunction (see Table S1). The piglets
were euthanized and the entire heart was rapidly removed,
weighed, and photographed while still beating. Then the isolated
heart was placed on an ice-cold petri dish, partially sectioned at
the midpoint of the LV length and photographs of the open
ventricular chambers were taken. Immediately after this step, the
LV free wall (LVFW) and left atrium (LA) were dissected into
several samples (100–200 mg each). Samples were frozen in liquid
nitrogen immediately after isolation and then stored until use at
280uC. The thickness of the LVFW was measured using digitized
photoimages of the ventricular-chamber cross-sections as de-
scribed [22,26].
Heart failure patient samples
Human heart samples were obtained from the heart tissue bank
set up by MGC-L at the University Hospital Center of La Corun˜a
(La Corun˜a, Spain). Written informed consent was obtained from
patients or their relatives, and the use of human cardiac tissues was
approved by the Ethical Committee of Clinical Investigation of
Galicia, Spain (approval Nu: 2007/239). The investigation
conforms to the principles outlined in the Declaration of Helsinki.
RNA and protein expression were assayed in explanted hearts
from end-stage heart failure (HF) transplantation patients with
ischemic (ICM) or idiopathic dilated cardiomyopathy (DCM) and
compared with samples obtained from non-failing donor hearts
that did not meet criteria for transplantation. All HF patients
(functionally classified according to the New York Heart
Association criteria) manifested a severely reduced systolic
function; the donor group was not known to have any history of
overt cardiovascular disease (see Table S2). Transmural samples
biopsied from the anterolateral wall of the left ventricle (LV) of
failing and non-failing human hearts were stored at 280uC until
assayed for RT-PCR and Western blotting.
RNA extraction and reverse transcription
Deep-frozen samples of piglet and human myocardium were
directly disrupted in RLT buffer (Qiagen, Madrid, Spain) using a
high-speed rotor-stator homogenizer (Ultra-Turrax T8, Ger-
many), digested with Proteinase K (Qiagen), loaded onto RNeasy
Mini/Midi columns (Qiagen), subjected to on-column digestion of
DNA with RNase-free DNase (Qiagen), and processed in
accordance with the manufacturer’s recommendations. Total
RNA from cultured HL-1 and Sol8 cells was extracted with the
TriPure isolation reagent (Roche Diagnostics, Barcelona, Spain),
treated with RNase-free DNase (Roche) for 1 h at 37uC and
purified using a standard phenol–chloroform protocol. RNA yield
and purity was determined spectrophotometrically, and RNA
integrity was verified by running samples on 1.2% agarose gels and
staining with ethidium bromide. Resulting RNA preparations
were resolved in nuclease-free water (Ambion, Madrid, Spain) and
kept at 280uC. Two microgram aliquots of individual total RNA
were reverse transcribed using SuperScript III or SuperScript
RNase H-minus (Invitrogen, Barcelona, Spain) reverse transcrip-
tase and oligo-dT primers according to the manufacturer’s
instructions. Negative control reactions were performed in the
same conditions without reverse transcriptase.
Microarray
Total RNAs isolated from LV biopsies of three failing (i.e., Dox-
injected) and three non-failing (i.e., PBS-injected) piglets were
transported on dry ice to the ‘‘KFB – Center of Excellence for
Fluorescent Bioanalytics’’ (University of Regensburg, Regensburg,
Germany) and the quality of RNAs was assessed by using gel
electrophoresis and spectrophotometry running eukaryotic total
RNA Nano Series II program. The qualified RNA samples were
independently hybridized on the Affymetrix GeneChip Porcine
Genome Array (Affymetrix, Santa Clara, USA). Sample process-
ing, array hybridization, scanning, and quantification were
performed at the Affymetrix Service Provider and Core Facility,
‘‘KFB – Center of Excellence for Fluorescent Bioanalytics’’
(University of Regensburg, Regensburg, Germany; www.kfb-
regensburg.de) as described in the Affymetrix GeneChip Expres-
Pitx2 and Myf5 in Heart Failure
PLOS ONE | www.plosone.org 2 March 2014 | Volume 9 | Issue 3 | e90561
sion Analysis Technical Manual. Briefly, the Ambion Messa-
geAmp Premier kit, starting with 150 ng total RNA, was used for
labeling. Hybridization was followed standard Affymetrix protocol
in Affymetrix GeneChip Hybridization Oven 640. All chips passed
standard quality controls to eliminate scans with abnormal
characteristics (high versus low affinity binding). The scanning
and image acquisition were performed by using the Affymetrix
GeneChip Scanner 3000 7G and core software GCOS v.1.4.
Expression data generation was performed by using the Affymetrix
GeneChip Operating Software (GCOS v. 1–4; MAS5 algorithm
with default settings). A set of the algorithms implemented in the
Affymetrix Microarray Suite Version 5.0 was used for statistical
treatment of the data. Genes were considered as altered if the
folds-change was at least 2.0 and adjusted p value #0.05. The
complete microarray data is available at NCBI through GEO
(Gene Expression Omnibus) accession number GSE30110
(http://www.ncbi.nlm.nih.gov/geo).
Conventional PCR
Conventional PCR was performed in a Biometra II system
(Gottingen, Germany) as described [24]. The piglet LV/LA
cDNAs were used as templates to detect different Pitx2 transcript
variants using the primers indicated in Table S3. The plasmid
DNAs encoding pig full-length Pitx2a, Pitx2b and Pitx2c were used
as a positive reference control. All PCR setups, including no-RT
and no template (NT) controls, were performed at least in
duplicate. Each PCR sample was resolved on a 2% agarose gel,
and PCR products were visualized with ethidium bromide staining
and UV illumination. Band intensity was estimated by densitom-
etry (VersaDoc 1000) and Quantity One software (Bio-Rad,
Madrid, Spain). The PCR products were cloned and sequenced
(Secugen, Madrid, Spain) to confirm their identity.
Real-time quantitative PCR (qRT-PCR)
qRT-PCR was performed on Bio-Rad IQ5 instrument (Bio-
Rad, Madrid, Spain) and MxPro Mx3005p PCR thermal cycler
(Stratagene, Madrid, Spain) using, respectively, SYBR Green (Bio-
Rad, Madrid, Spain) and DyNAmo HS SYBR Green (Thermo
Scientific, Madrid, Spain) master mix as described previously
[24,27]. The primer pairs were located in different exons to rule
out genomic DNA amplification. Each primer pair used yielded a
single peak of dissociation on the melting curve and a single band
with the expected size on PAGE gels. Identity of the PCR products
was confirmed by sequencing. NT and non-RT RNA template
reactions were used as negative controls. All PCR setups were
performed at least in duplicate. Relative quantifications were
calculated with the comparative DCt cycle method with normal-
ization to the expression of housekeeping genes coding for
ribosomal protein L19 (Rpl19), glyceraldehyde-3-phosphate dehy-
drogenase (Gapdh) and b-D-glucuronidase (Gusb). The efficiency of
target and reference amplifications was tested to be approximately
equal. Primer sequences and additional data are given in Table
S3.
Plasmid constructs
Pig Pitx2a (sequence deduced from the swine genomic sequence
NW_003610943) and Pitx2c (NM_001206435) were amplified
from oligo-dT-primed cDNA from left atrium of newborn piglets;
pig Pitx2b (sequence deduced from the swine genomic sequence
NW_003610943) was amplified from skeletal muscle cDNA of 20-
day-old neonatal animals. Each of the full-length Pitx2 constructs
was directionally cloned into p3xFLAG-CMV-14 expression
vector (Sigma, Madrid, Spain) at the EcoRI (59) and BamHI (39)
restriction sites and verified by sequencing [28]. Mouse full-length
Pitx2c (NM_001042502.1) was amplified from Sol8 myoblast
cDNA by PCR with specific primers containing HindIII and XbaI
restriction sequences [27]. Subsequently, the PCR product was
inserted into the pcDNA3.1/Zeo(-) plasmid (Invitrogen, Barce-
lona, Spain), which was modified to generate the V5-tagged Pitx2c
as reported [29]. The plasmids were purified by using a PureLink
HiPure plasmid filter purification kit (Invitrogen, Barcelona,
Spain) according to the manufacturer’s protocol. Purified plasmids
were formulated in nuclease-free water (Ambion, Madrid, Spain).
Cell culture and transfection in vitro
The following cell lines were used: COS-7 (a fibroblast-like cell
line derived from monkey kidney tissue was purchased from the
European Collection of Cell Cultures, Salisbury, Wiltshire, UK),
HL-1 (a mouse atrial cardiac myocyte cell line was provided by
Prof. William C. Claycomb [30]), and Sol8 (a mouse skeletal
myogenic cell line was purchased from the American Type
Culture Collection, Barcelona, Spain). COS-7 and Sol8 cells were
cultured in Dulbecco’s modified Eagle’s Medium (Gibco, Barce-
lona, Spain) supplemented with 10% fetal bovine serum and
penicillin–streptomycin–glutamine (Gibco); HL-1 cells were cul-
tured in similarly supplemented Claycomb’s growth medium [30].
Cells were trypsinized at 70–80% confluence and cell numbers
were determined using an automated cell counter (Countess,
Invitrogen, Barcelona, Spain). Cells were plated at a density of 105
cells per 35 mm well, allowed to attach overnight and transfected
with plasmids expressing: (1) FLAG-tagged pig Pitx2a, Pitx2b and
Pitx2c (COS-7 cells/500 and 1000 ng of plasmid DNA), and (2)
V5-tagged mouse Pitx2c (HL-1 and Sol8 cells/100–400 ng of
plasmid DNA). All transfections were carried out with Lipofecta-
mine LTX and PLUS Reagents (Invitrogen, Barcelona, Spain)
following the manufacturer’s instructions. For each plasmid, from
three to six separate transfection assays were employed, and in
each assay, transfections were performed in duplicate. The
transfection protocol typically yielded 60–70% transfection effi-
ciency, as revealed by transfection of CMV-EGFP (enhanced
green fluorescent protein) vector [27]. Controls consisted of mock-
and empty vector–transfected cells. For Pitx2c-silencing experi-
ments, HL-1 and Sol8 cells were seeded in twenty four-well plates
(30000 cells per well) and co-transfected with V5-tagged Pitx2c (at
400 ng) and Pitx2c-specific siRNA heteroduplex [13] (at 80 nM)
using the Lipofectamine 2000 Transfection Reagent (Invitrogen,
Barcelona, Spain), following the manufacturer’s protocol. The cells
transfected with V5-tagged Pitx2c, under the same conditions, were
used as a reference. In each assay, transfections were performed in
triplicate. The cells were harvested at 24–48 hours after transfec-
tion and processed for RNA and protein extraction as described
[24,27].
Antibodies
The following primary antibodies were used: (1) rabbit
polyclonal antibodies to PITX2A,B,C (Capra Science, A¨ngelholm,
Sweden; at 1:2000 dilution), (2) rabbit polyclonal antibodies to
PITX2B (Capra Science, A¨ngelholm, Sweden; at 1:1000 dilu-
tion).The specificity of the anti-PITX2 antibodies was indepen-
dently validated in this study by Western blot analysis of COS-7
cells expressing each PITX2 isoform (see Fig 1 A, B), (3) rabbit
monoclonal antibodies to MYF5 (Abcam, Cambridge, UK; at
1:10000 dilution), (4) rabbit polyclonal antibodies to cardiac
troponin I (Abcam, Cambridge, UK; at 1:40000 dilution), (5)
rabbit polyclonal antibodies to cardiac calsequestrin-2 (Abcam,
Cambridge, UK; at 1:10000 dilution), (6) rabbit polyclonal
antibodies to ANKRD1 (at 1:1000 dilution) were generated by
Davids Biotechnologie (Regenburg, Germany) using the N-
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terminal region of pig ANKRD1 as immunogen [22], (7) mouse
monoclonal anti-FLAG M2 antibody (Sigma, Madrid, Spain; at
1:5000 dilution), (8) mouse monoclonal anti-V5 antibody (Sigma,
Madrid, Spain, at 1:5000 dilution), and (9) mouse monoclonal
anti-GAPDH antibody (Sigma, Madrid, Spain, at 1:10000
dilution). Secondary peroxidase conjugated anti-rabbit and anti-
mouse IgG (Fab-specific) antibodies were purchased from Sigma
(Madrid, Spain).
SDS-PAGE and Western blotting
Tissue/cell samples were homogenized in standard 2x Laemmli
buffer (Invitrogen, Barcelona, Spain) supplemented with complete
protease inhibitor cocktail (Roche, Madrid, Spain) as previously
described [24,25]. Following centrifugation at 20000 g for 30
minutes, the concentration of supernatant proteins was analyzed
using the Bio-Rad DC Protein Assay Kit (Bio-Rad, Hercules,
USA) according to the manufacturer’s protocol. The protein
extracts were normalized to total protein concentration; the results
of normalization were confirmed by SDS-PAGE and Coomassie
staining before Western blotting analysis [25,31]. Protein super-
natants (loading range of 5–15 mg/run) were resolved on a 12%
SDS-PAGE (Mini-Protean-III, Bio-Rad, Hercules, USA) and
blotted onto PVDF-membranes (Hybond-P, Amersham Biosci-
ences, Barcelona, Spain). Molecular weight (MW) standards
(Precision Plus Protein WesternC Standards from Bio-Rad and
SeeBlue Plus2 Pre-Stained Standard from Invitrogen) were
included on each gel. Blots were probed with the antibodies
indicated above and visualized by the Super-Signal West Pico
chemiluminescent substrate (Pierce Biotechnology, Madrid,
Spain). Equivalence of protein loading was confirmed by Amido-
Black 10B (Merck, Barcelona, Spain) staining of blots after
immunodetection. The blots were re-probed with anti-cardiac
calsequestrin 2 and anti-GAPDH antibodies as additional control
for loading. Quantification of Western blot signals was obtained by
using a Bio-Rad GS800 calibrated densitometer with Quantity
One software.
Statistical Analysis
Values presented are expressed as mean 6 S.E.M. All
comparisons between groups were performed using an unpaired
Student’s t test. Differences were considered statistically significant
for p value #0.05.
Results
PITX2C is the predominant splice-variant isoform in
porcine and human left ventricular myocardium
PITX2 protein expression was studied by Western blot in left
ventricular (LV) samples of normal porcine and non-failing human
hearts. The FLAG-tagged constructs containing each of the three
different PITX2 isoforms (Fig. 1 A) were used to evaluate the
specificity of antibodies against PITX2A,B,C. Lysates from COS-7
cells transiently transfected with constructs were probed by
Western blotting with anti-FLAG and anti-PITX2A,B,C antibod-
ies (Fig. 1 B). Anti-FLAG detection revealed the expression of
three PITX2 isoform-specific products, each migrating in SDS-
PAGE as one band. The same protein products were also detected
by anti-PITX2A,B,C antibodies indicating that these antibodies
specifically recognize all PITX2 isoforms equally well (Fig. 1 B,
right panel). However, only one band, with MW around 38–
39 kDa corresponding to the expected size of PITX2C, could be
seen in both porcine and human LV samples when probed with
anti-PITX2A,B,C antibodies (Fig. 1 C). After neutralization of
these antibodies with FLAG-tagged PITX2C protein, neither
band was detected on the LV-derived blots. In addition, the
antibodies against PITX2B isoform did not reveal any band in
LV-extracts assayed under the same experimental conditions.
The results of Western blot assays were consistent with the
expression levels of Pitx2 variants determined by PCR analysis
(Fig. 1 D). In control experiments, with the use of Pitx2-encoding
plasmid DNAs as templates, each of three Pitx2 transcript variants
was amplified with comparable efficiency (Fig 1 D, left panel).
However, only the largest Pitx2c variant was detected in LV
samples using the same primer sets (Fig. 1 D, right panel). Taken
together, the results strongly evidenced that PITX2C is the most
abundant and predominant isoform in the LV of pigs and humans.
Ventricular Pitx2c expression is downregulated after birth
but markedly reactivated in piglet diastolic heart failure
In neonatal piglets, the LV undergoes rapid hypertrophic
growth as development proceeds [22,32]. Likewise, in this work,
we found that the average LVFW thickness was approximately
2-fold higher in normal 30-day-old piglets than in newborns
(Fig. 2 A, B). Comparative qRT-PCR analysis of the LV-samples
from these two groups of normal animals revealed that Pitx2c
mRNA levels at birth are 16-fold higher than are those detected in
30-day-old animals (Fig. 2 C). These results suggest that a rapid
progression of LV-concentric remodelling is associated with
downregulation of Pitx2c expression in healthy neonatal piglets.
By utilizing our protocol [24,25], diastolic heart failure (DHF)
syndrome was induced in 6-day-old piglets by a single Dox
injection. At day 30, neonatal piglets developed a diastolic
dysfunction resulting in pulmonary congestion, but with nearly-
normal (‘‘preserved’’) systolic function in terms of LV-end systolic
pressure and global cardiac output values. The average fold-
increase of both the normally spliced Nppb (natriuretic peptide
precursor B) and DE2-Nppb (exon 2-skipped) mRNA [33] in the
failing versus control LV myocardium was 5.8 and 9.4,
respectively (see Table S1).
We quantified the relative amounts of the Pitx2c splice variant in
the LV myocardium of control (i.e., PBS-injected) and experi-
mental (i.e., Dox-injected) piglets (Fig. 2 D) by qRT-PCR.
Expression of Pitx2c transcript was enhanced 6.7-fold in the failing
versus control myocardium. The specificity of the unique Pitx2c
Figure 1. PITXC, but not PITX2A and PITX2B, is detected in the normal porcine and human left ventricular myocardium. A -
Schematic representation of FLAG-tagged Pitx2a, Pitx2b and Pitx2c constructs. 2–6 – exons. The approximate location of the primers for downstream
PCR analyses (D) is indicated. The expected size of the corresponding amplicons is shown in black lines. B - Lysates of COS-7 cells transfected with
FLAG-tagged Pitx2 constructs were electrophoresed and immunoblotted with anti-FLAG or anti-PITX2A,B,C antibodies. Cells transfected with: vector
only (Lane 1), Pitx2c (Lane 2), Pitx2b (Lane 3) and Pitx2a (Lane 4) constructs. C - Lysates of COS-7 cells transfected with FLAG-tagged Pitx2c (Lane 1) or
Pitx2b (Lane 1*) and left ventricle (LV) samples from normal 30-day-old porcine (Lane 2 and 3) and non-failing human (Lane 5, 6) hearts were blotted
and probed with anti-PITX2A,B,C or anti-PITX2B antibodies. Lane 4 – Precision Plus WesternC Standards, kDa. Protein load – membrane stained with
Amido Black 10B. Anti-PITX2A,B,C+PITX2C – antibodies neutralized by the extract of COS-7 cells transfected with FLAG-tagged Pitx2c construct. D -
PCR amplifications of Pitx2 transcript variants using the Pitx2-encoding plasmid DNAs (left panel, lane 1–6) or porcine LV cDNA (right panel, lane 7–12)
as templates. Reactions were run in duplicate using 2-fold dilutions of both templates with each primer pairs. L – DNA size standards (GeneRuler DNA
ladder mix; Fermentas).
doi:10.1371/journal.pone.0090561.g001
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Figure 2. In the pig left ventricular myocardium, Pitx2c expression is downregulated after birth but re-activated in DHF. A, B - Cross-
sections through left ventricular (LV) chambers of newborn (NB) and 30-day-old (30 d) piglets (Bar – 1 cm) and LVFW thickness values, respectively. C
- Overall relative levels of Pitx2c transcript in LV-samples of newborn versus 30-day-old animals, *p#0.05. D - Overall relative levels of Pitx2c transcript
in LV-samples of PBS-injected versus Dox-injected 30-day-old piglets, *p#0.05. E - Representative Western blots of PITX2C levels in the LV
Pitx2 and Myf5 in Heart Failure
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amplification product was determined by melting curve and
PAGE analyses (Figure S1 A–D). A similar 6.5 fold-increase was
observed for the PITX2C protein in failing as compared to non-
failing piglet LV myocardium (Fig. 2 E–I).
Thus, these results demonstrated that expression of Pitx2c,
which is physiologically downregulated in the early postnatal
heart, becomes significantly re-activated in an experimental DHF
setting.
Myf5 is identified as the most upregulated gene among
Pitx2 targets in piglet failing myocardium
Marked reactivation of PITX2C protein expression suggested
that downstream targets could also be activated in DHF
myocardium. A variety of putative targets of Pitx2 have been
suggested over the years, many in associative gene expression
studies of non-cardiac tissues by using microarray-based methods
[34–38]. In adult ventricular myocardium, the exact Pitx2
signalling pathway is not defined, nor the Pitx2 targets involved.
Our microarray expression profiling of LV-samples from non-
failed and failed porcine hearts revealed that Pitx2 upregulation is
associated with increased expression of a restrictive set of known
Pitx2 target genes (Table 1). It is noteworthy that previous studies
have demonstrated that these genes have PITX2 binding site(s) in
their promoter region, as demonstrated by chromatin immuno-
precipitation and functional promoter-reporter assays (see refer-
ences in Table 1). Changes in the expression of three transcription
factors, Myf5, Pax3, and FoxJ1, as well as Pitx2 itself were further
verified by real time qRT-PCR in the same (three failing versus
three non-failing) samples used in microarray assays (Table 1).
Among Pitx2 targets, most notable was the marked upregulation of
the myogenic factor MYF5 in DHF myocardium. mRNA levels
for the Pax3 transcription factor, which can activate Myf5 in
embryonic muscle progenitor cells [39], were also elevated in
failing LV-myocardium, although to a lesser extent as compared to
Pitx2c and Myf5 (see Table 1). Pax3, Pitx2, and Myf5 are upstream
genes which differentially regulate the kernel myogenic program in
cell- and time-dependent manner [40,41]. However, the expres-
sion of downstream myogenic factors - MYOG (myogenin; see
Fig. 3 A, right panel), MYOD, and MYF6 (also known as MRF4) -
was not significantly altered in failing compared to non-failing LV
myocardium. In addition, there were subtle differences in the
expression levels of skeletal muscle-specific genes (Tnnt1, Tnnt3,
Myh4, and Tpm2), with exception of the Myl1 gene which
expression was markedly downregulated in failing myocardium
(see Table S4 and complete microarray data set at GEO accession
number GSE30110). LV expression of the FoxJ1 (forkhead box J1)
transcription factor, which is involved in cardiac morphogenesis
and remodelling [42], was moderately upregulated in Dox-injected
versus that in control PBS-injected animals (see Table 1).
Recently, a search for cardiac Pitx2 targets by ChIP-Seq and
microarray assays revealed several novel putative targets nega-
tively regulated by Pitx2 in transfection assays using the 293FT cell
line derived from human embryonic kidney [18]. The expression
of these genes (coding of calcium voltage-gated channel subunit
alpha-1d; potassium voltage-gated channel, KQT-like subfamily,
member 1; caveolin 1; emerin) was not altered in LV myocardium
of Dox-injected versus PBS-injected piglets (see complete micro-
array data set at GEO accession number GSE30110).
We further validated the upregulation of Myf5 in DHF LV-
myocardium by performing quantitative RT-PCR and Western
blot analyses in a larger cohort of Dox- versus PBS-injected
animals. On average, the level of Myf5 transcript was enhanced
4.8-fold in the failing (n = 12) versus control (n = 8) LV-myocar-
dium (Fig. 3 A, left panel). The specificity of the unique Myf5
amplification product was determined by melting curve and
PAGE analyses (see Figure S2). A seemingly similar 3.5 fold-
increase was observed for the MYF5 protein in failing as
compared to non-failing piglet LV myocardium (Fig. 3 B–D).
Recent clinical evaluations indicated that LV diastolic dysfunc-
tion can result in functional and structural remodelling of the left
atrium (LA) in patients [43,44]. In line with these data, we studied
the expression of Pitx2c and Myf5 in LA samples from Dox- versus
PBS-injected piglets. As revealed by Western blot, the levels of
both PITX2C and MYF5 were about 10-fold higher in the LA of
Dox-treated as compared to those in the LA of PBS-treated piglets
(Fig. 3 E–G). Only the 38-kDa band, corresponding to the porcine
PITX2C isoform, was detected on LA-derived blots probed with
anti-PITX2A,B,C antibodies (Fig. 3 E), although these antibodies,
as we demonstrated, recognize the all PITX2 isoforms (see Fig. 1
B, right panel). The RT-PCR analysis for LA-samples (Fig. 3 H)
myocardium of PBS-injected (Lane 1, 2, 3) and Dox-injected (Lane 4, 5, 6) 30-day-old piglets. Each LV-sample (1–6) was derived from an individual
animal. Western blot replicates were probed with antibodies against: (F) - cardiac calsequestrin 2 (CASQ2) and (G) - cardiac troponin I (TNNI3). MW
values (kDa) of the bands detected are shown. H – Membrane stained with Amido Black 10B. I - Overall relative levels of PITX2C protein in LV-samples
as based on average values from each group studied. *p#0.05.
doi:10.1371/journal.pone.0090561.g002
Table 1. Upregulation of genes sensitive to Pitx2 dosage in the piglet DHF model.
Gene coding for Gene symbol Fold change
PITX2 binding to the
promoter Reference
microarray qRT-PCR
Paired-like homeodomain 2 Pitx2 2.14 6.6061.6*
Natriuretic peptide precursor A Nppa 4.42 HV + [73]
Cyclin D2 Ccnd2 2.38 HV + [51]
Forkhead box protein J1 Foxj1 2.66 3.2060.4 + [74]
Myogenic factor 5 Myf5 5.15 4.8060.5 + [57]
Paired box 3 Pax3 3.39 1.8060.3 + [45]
Three pairs of failing-non failing samples were assayed by both microarray and qRT-PCR. *Quantitative RT-PCR analysis with the use of the primer pair (350–353, see
Table S3) annealing to the sequence common to the different Pitx2 variants. HV – highly variable expression within each sample sets.
doi:10.1371/journal.pone.0090561.t001
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revealed the predominant expression of the Pitx2c variant, while
other Pitx2 alternative transcripts were either not detected (Pitx2b)
or detected in traces (Pitx2a).
Collectively, the findings from the porcine model of DHF
revealed a strong upregulation of Pitx2c and Myf5 under stress
conditions, suggesting that Pitx2c could be involved in transcrip-
tional regulation of Myf5 expression, and probably to a lesser
extent of FoxJ1 too, in postnatal cardiomyocytes.
Forced expression of Pitx2c increases the expression of
Myf5 in cultured cardiomyocytes
To explore the possibility that Pitx2c may activate Myf5 and/or
FoxJ1 expression specifically in cardiomyocytes, we overexpressed
the full-length Pitx2c variant in HL-1 cardiomyocyte as well as
undifferentiated Sol8 skeletal muscle cell lines. The Sol8 cell line
was used as a control since, as previously demonstrated, Pitx2c
overexpression promotes proliferation and arrests muscle differ-
entiation of Sol8 cells [45].
Transient transfections of HL-1 cardiomyocytes strongly
enhanced, in a dose-dependent manner, the expression of the
Myf5 gene compared to that in mock- and empty vector-
transfected cells. This effect appears to be cell-type dependent,
as no stimulation of Myf5 transcript expression was observed in
Pitx2c-transfected Sol8 myoblasts (Fig. 4 A). In this direction, the
inhibition of Pitx2c overexpression, using Pitx2-siRNAs, led to a
decrease of Pitx2c-induced activation of the Myf5 gene in HL-1
cardiomyoblasts, whereas co-transfection with Pitx2c siRNA did
not affect the basal level of Myf5 expression in Pitx2c-transfected
Sol8 myoblasts (Fig. 4 B). The ability of Pitx2c to activate Myf5
expression in HL-1 cardiomyoblasts was further confirmed by
Western blot analysis. Ectopic PITX2C upregulation resulted in
activation of MYF5 protein expression in HL-1, but not in Sol8
cells (Fig. 4 C). Under our experimental conditions, we could not
detect any MYF5 protein in either control or Pitx2c-transfected
Sol8 myoblasts.
With respect to expression of FoxJ1, the results of Pitx2c
transfections of HL-1 cells were not very conclusive but there
appeared to be a statistically significant and slightly dose-
dependent increase of FoxJ1 expression as compared to control
cells (see Figure S3). By contrast, in transfected Sol8 myoblasts
FoxJ1 was downregulated at doses of 100 and 200 ng of Pitx2c
plasmid DNA followed by a return to basal levels at a highest dose
used (400 ng). The cause of this down-regulation of FoxJ1
expression is not known at present.
We next asked whether forced expression of Pitx2c is able to
modulate the expression of PAX3 and MYOG myogenic factors in
HL-1 versus Sol8 cells. We found that forced Pitx2c expression
does not affect the levels of Pax3 expression in either HL-1 or Sol8
transfected cells, but results in decreased expression of the Myog
gene selectively in Sol8 undifferentiated myoblasts (see Figure S3).
The latter is in accordance with previous experimental data
reporting Myog downregulation in Sol8 myoblasts transfected with
Pitx2c expression vectors [27,45].
Essentially, data from transfection assays showed that Pitx2c
upregulation does result in strong and dose-dependent activation
of Myf5 expression in cardiomyocytes and to a minor extend of
FoxJ1.
Ventricular Pitx2c expression is reactivated in human
systolic heart failure
Controversy about whether diastolic (DHF) and systolic HF
(SHF) represent overlapping [46] or distinct [47] phenotypes of
severely impaired cardiac function remains unsolved. We aimed to
investigate whether re-activation of Pitx2c expression in DHF, as
revealed in the porcine model, is also related to SHF in patients
undergoing heart transplantation due to dilated (DCM) or
ischemic cardiomyopathy (ICM). On average, the level of
expression of the Pitx2c transcript was nearly 6-fold (DCM) and
8-fold (ICM) higher in LV tissue samples from explanted hearts as
compared with those from donor human hearts (Fig. 5 A).
However, Western blotting analysis showed that PITX2C protein
upregulation in falling human myocardium was significantly less
(2–3-fold increase) than that observed at the RNA level (see Fig. 5
B, C). In the studied failing myocardium, the expression of
ANKRD1 (ankyrin repeat domain 1 protein), the surrogate
marker of HF [48], was significantly upregulated (Fig. 5 B, E),
while the levels of TNNI3 (cardiac troponin I; the marker of acute
myocardial ischemia) were unchanged or slightly augmented as
compared to non-failing samples (see Fig. 5 B).
In addition, we studied the expression of Myf5 and Myog genes
in human failing hearts. Expression of Myf5 was found to be nearly
2-fold decreased at both transcript (Fig. 5 A) and protein (Fig. 5 B,
D) levels in falling as compared to non-failing human myocardi-
um, whereas the expression of Myog was unchanged (Fig. 5 A).
Although not statistically significant, there was a trend toward less
decrease of MYF5 protein in ICM than in DCM samples
(Fig. 5 D).
Collectively, the results suggest that Pitx2c re-activation in
ventricular myocardium is a common molecular signature of HF
with preserved (DHF) as well as reduced systolic (SHF) function,
while the expression of Myf5 is distinct between the two HF
phenotypes studied.
Discussion
In this paper we provide what are, to our knowledge, the first
reported results, demonstrating: (1) the re-activation of Pitx2c
expression in failing myocardium in different HF settings, (2) the
marked upregulation of Myf5 myogenic factor expression in failing
ventricular and atrial myocardium as well as in cultured
cardiomyocytes in response to forced expression of Pitx2c, and
(3) the expression of the large repertoire of myogenic regulatory
factors (MRFs) in normal and failing myocardium. Each of these
Figure 3. Expression of Myf5, but not Myog, is upregulated in the failing pig left heart as determined by qRT-PCR and Western blot
analyses. A – Relative levels for Myf5 (left) and Myog (right) transcripts in the left ventricular (LV) samples from PBS- and Dox-injected piglets. B -
Representative Western blots of MYF5 levels in the LV samples from PBS- (Lane 1, 2, 3) and Dox-injected (Lane 4, 5, 6) piglets (blots probed with anti-
PITX2A,B,C antibodies). Western blot replicates were probed with antibodies against cardiac calsequestrin 2 (CASQ2) and cardiac troponin I (TNNI3).
MW values (kDa) of the bands detected are shown. C – Control of protein loading: Western blot membrane probed with anti-MYF5-antibodies was
then stained with Amido Black 10B to detect blotted proteins. D – Overall relative levels of MYF5 protein in LV-samples as based on average values
from each group studied. *p#0.05. E – Representative Western blots of PITX2C and MYF5 levels in the left atrium (LA) from PBS- (Lane 1, 2, 3) and
Dox-injected (Lane 4, 5,6) piglets. MW values (kDa) of the bands detected are shown. F – Membrane stained with Amido Black 10B. G – Overall relative
levels of PITX2C and MYF5 in LA-samples as based on average values from each group studied. *p#0.05. H – RT-PCR amplifications (Lane 1–6) of Pitx2
transcript variants using the porcine LA cDNA as template. Reactions were run in duplicate using 2-fold template dilutions with each primer pairs. L –
DNA size standards (GeneRuler DNA ladder mix; Fermentas).
doi:10.1371/journal.pone.0090561.g003
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data sets is discussed in the context of the underlying molecular
mechanisms of HF.
Activation of myocardial PITX2c expression as a hallmark
of heart failure
A possible involvement of PITX2C in ventricular HF has not
yet been explored. We demonstrate herein a similar upregulation
of Pitx2c expression in the LV myocardium, at transcript and
protein levels, in a porcine model of DHF as well as in patients
with end-stage SHF. In patients, LV diastolic dysfunction can lead
to elevation of LA pressure, resulting in increased LA wall tension
and progressive LA dilatation, thereby increasing the risk and
frequency of atrial fibrillation development [44,49]. By using the
porcine DHF model, we evidence that Pitx2c is upregulated in the
LA myocardium. This new observation adds an additional layer of
complexity to the challenge linking perturbations of Pitx2c
expression in the LA to the development of atrial fibrillation
[11]. Mechanistically, the results of this study strongly suggest that
Pitx2c activation is a common feature of the failing heart, in line
with recent reports of myocardial Pitx2c upregulation in HF due to
ventricular septal defects in human foetuses [50]. The question is
whether Pitx2c upregulation deteriorates the failing myocardium as
one of the factors for HF progression or its activation is merely a
secondary manifestation of impaired LV function that might even
have a compensatory effect in HF? Certainly, any answer to such a
question is still speculative as current knowledge on Pitx2c
functions in postnatal ventricular myocardium is incomplete and
largely uncertain. In addition, the role of Pitx2c in failing
myocardium may be multifaceted depending on the cause, type,
stage, and severity of HF. Our results in fact suggest that an
excessive re-activation of Pitx2c expression could contribute to an
overall disturbance of the cardiac gene regulatory network in
failing myocardium.
Pitx2 expression is upregulated by a canonical Wnt/b-catenin
signalling pathway involved in activation of cell proliferation of
embryonic cardiac precursors [51]. However, the canonical Wnt
signalling negatively regulates the proliferation of adult cardiac
progenitor cells, contributing to negative LV-remodelling [52].
There is substantial evidence that inhibition of the canonical Wnt/
catenin pathway can be beneficial for HF [53]. Recently, Pitx2 is
recognized for being a downstream transcription factor in the
TGF-b (transforming growth factor beta) signalling pathway in
non-muscle cells [36]. Myocardial TGF-b signalling is activated in
animal models of myocardial infarction and cardiac hypertrophy,
and patients with dilated and hypertrophic cardiomyopathy.
Reducing of TGF-b signalling is seen as a promising therapeutic
approach for cardiovascular diseases (reviewed in [54,55]).
Notably, our microarray analysis revealed that the components
of the TGF-b signalling pathway, such as TGFbR3 (TGFb
receptor 3; 6.2-fold increase) and SMAD3 (2.0-fold increase), are
upregulated in the failing porcine LV-myocardium (see Table S4).
Hence, it is likely that upregulation of the canonical TGF-b
signalling pathway, that is believed to represent a maladaptive
response of diseased heart to stress, may contribute to Pitx2c re-
expression in porcine and human myocardium in advanced and
late stages of HF. The endogenous targets of Pitx2 in the adult
heart remain largely enigmatic. Many genes involved in cell-
junction assembly, ion transport and cell proliferation/migration
were found to be upregulated in mouse mutants with conditionally
inactivated Pitx2 in the postnatal atrial myocardium, but no
supporting molecular evidence of Pitx2-dependent downregulation
of these genes in cardiomyocytes has been reported [18].
Although the data mentioned above do not directly involve
Pitx2c signalling in pathogenesis of HF, our preliminary assump-
tion is that Pitx2c re-activation in the failing heart might be
maladaptive. The finding that forced expression of Pitx2c
dramatically upregulates the myogenic transcription factor
MYF5 in cultured cardiomyocytes, lends some credence to this
suggestion.
Myf5 upregulation as a consequence of Pitx2c activation
Given that gene regulatory networks for cardiac and skeletal
muscle are different in many ways, the enhanced expression of two
key regulators of skeletal myogenesis - Myf5 and Pax3 - in failing
porcine myocardium has attracted our special attention. To
establish whether the upregulation of these genes is mediated via
Pitx2c, HL-1 cardiomyocytes (with barely detectable Myf5 tran-
script levels) and Sol8 skeletal myocytes (with low detectable Myf5
transcript levels) were transiently transfected with Pitx2c expression
vector. Forced expression of Pitx2c dramatically stimulated the
expression of Myf5 (at both transcript and protein levels)
exclusively in HL-1 cardiomyocytes, suggesting such regulation
is cell-content dependent. The observation that the expression of
Myf5 is decreased following Pitx2c silencing in only HL-1
cardiomyoblasts, overexpressing Pitx2c, does also argue in this
direction. In Pitx2c-transfected HL-1 cardiomyocytes, augmented
expression of both Pitx2c and Myf5 did not affect Myog levels,
contrary to Myog downregulation in Sol8 skeletal myoblasts
overexpressing Pitx2c. The Pax3 expression was not significantly
altered in HL-1 cardiomyocytes that transiently overexpressed
Pitx2c. The latter suggests that Pax3 does not contribute to
activation of Myf5 expression in HL-1 cardiomyocytes, similarly to
that occurring in the progenitor cells of postnatal skeletal muscle
[56].
The Pitx2-binding sites in the Myf5 promoter region are
conserved among species, and two potential Pitx2-binding sites
exist in the mouse Myf5 promoter. It has been demonstrated that
PITX2 physically associates with these binding sites and activates
the Myf5 promoter in limb- and extra-ocular muscle-derived
precursor cell lines [57]. In addition, Pitx2 potently stimulates the
myogenic differentiation program in adult skeletal muscle satellite
cells [58]. The results of our transfection assays raise the intriguing
possibility that Pitx2-Myf5 expression crosstalk can also be
operative in cardiomyocytes. In this regard, expression of both
Pitx2 and Myf5 was detected in cardiomyocyte-like (CML) cells
generated from pluripotent stem cells of patients with DCM due to
mutations in the cardiac troponin T gene [59]. In-vitro forced
expression of sarcoplasmic reticulum Ca2+ ATPase (Serca2a)
improved contractility function of CML cells that, in turn, was
Figure 4. In vitro forced expression of Pitx2c results in increased Myf5 expression in cultured cardiomyocytes but not skeletal
myoblasts. A - Overall relative levels of Pitx2c (black) and Myf5 (grey) transcripts in HL-1 and Sol8 cells transfected with V5-tagged Pitx2c vector at
different doses (100-400 ng). CT – empty-vector transfected cells. Shown are results of qRT-PCR analysis. Data from six replicates of each transfection
were pooled and averaged. In controls, the relative levels of transcripts for Myf5 were assigned to a value of 1, whereas those for Pitx2c were assigned
to a value of 1024. *p#0.05. B – Overall relative levels of Pitx2c and Myf5 transcripts in HL-1 and Sol8 cells co-transfected with V5-tagged Pitx2c (at
400 ng) and Pitx2c-specific siRNA heteroduplex (at 80 nM). Data from three replicates were pooled and averaged. C - HL-1 and Sol8 cells transfected
with V5-tagged Pitx2c (at 100–400 ng) were pooled (from triplicate wells in each transfections), lysed, electrophoresed, and immunoblotted with
antibodies against PITX2A,B,C, MYF5 and GAPDH. MW values (kDa) of the bands detected are shown.
doi:10.1371/journal.pone.0090561.g004
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Figure 5. Pitx2c expression is reactivated, while expression of Myf5 is downregulated in human systolic heart failure as determined
by qRT-PCR and Western blot analyses. A - Overall relative levels of Pitx2c, Myf5, and Myog transcripts in the left ventricular (LV) samples from
non-falling (NF) and failing human hearts due to idiopathic dilated (DCM) and ischemic (ICM) cardiomyopathy. *p#0.05. B - Representative Western
blots of PITX2C levels (top) in the LV samples from NF (Lane 1–3), DCM (lane 4–6) and ICM (lane 7–9) failing hearts. Western blot replicates were
probed with antibodies against MYF5, cardiac calsequestrin 2 (CASQ2), cardiac troponin I (TNNI3) and ankyrin repeat domain 1 protein (ANKRD1). MW
values (kDa) of the bands detected are shown. Protein load - Membrane stained with Amido Black 10B. Overall relative levels of PITX2C (C), MYF5 (D)
and ANKRD1 (E) protein in LV-samples as based on average values from each group studied. *p#0.05.
doi:10.1371/journal.pone.0090561.g005
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associated with downregulation of Pitx2 and Myf5 mRNA levels in
Serca2a-transduced cells (see the data set available at NCBI
through accession number GSE35108). On the other hand, and
complementary to these results, ectopic overexpression of Myf5 in
the heart activates a skeletal muscle gene expression that results in
progressive cardiomyopathy [60,61]. The latter suggests that
aberrant Pitx2-Myf5 co-activation seen in our model of DHF may
negatively impact on diastolic cardiac function.
Formally viewed, our findings suggest the involvement of Pitx2c
in regulation of Myf5 expression in the stressed myocardium.
However, the expression of Myf5 is modulated by a large number
of endogenous signalling factors, each of which can have either
positive or negative effects on Myf5 expression, depending on cell
type and physiological/pathological context [40,62]. An inverse
correlation in expression of Pitx2c (i.e., upregulation) and Myf5
(i.e., downregulation) was detected in human samples of DCM and
ICM (see Fig. 5). The discordance in Myf5 expression in porcine
versus human failing myocardium could be attributable to
multiple factors, including differences in HF dysfunction pheno-
types (diastolic versus systolic HF), stage and severity of HF (mid-
advanced versus end-stage HF), age at which HF occurs (neonatal
versus adult/aged heart), and medication (non-drug for DHF
versus multidrug therapy for SHF). In addition, we observed a
certain variability in Pitx2c and Myf5 expression between DCM
and ICM samples (see Fig. 5). At the molecular level, the
difference in cardiac expression of inhibitors of skeletal myogenesis
might also play a role. Myostatin, a negative regulator of
myogenesis and Myf5/MyoD expression [63], is downregulated in
our model of porcine DHF [64], while significantly upregulated in
human HF due to DCM and ICM [65], supporting thus this
hypothesis.
Expression of the MRF transcriptional cassette in the
heart
In the present study we demonstrated the expression of Myf5 in
porcine and human LV-myocardium at both transcript and
protein levels via qRT-PCR and Western blotting, respectively (see
Fig. 3 and 5). Surprisingly, our gene expression studies revealed
that, in addition to the Myf5 gene, a number of genes involved in
regulation of skeletal myogenesis are also expressed in postnatal
pig (MyoD, Myog, Myf6/Mrf4, Pax3) and adult human (Myog)
myocardium. These data are consistent with detection of MyoD
expression in postnatal mouse heart [66] as well as MyoD, Myog
[67] and Myf5 [68] transcripts in postnatal/adult rat ventricular
myocardium.
Forced expression of MRFs, especially MyoD and Myf5, can
covert different non-muscle cell types into skeletal myoblasts in vitro
(reviewed in [69]. However, the ectopic misexpression of either
Myf5 or MyoD in the heart in-vivo, triggering skeletal muscle-
specific gene expression, does not lead to terminal skeletal muscle
differentiation [70,71]. It is tempting to speculate that cardio-
enriched miRs might suppress the expression level of MRFs, thus
preventing skeletal myoblast differentiation in postnatal myocar-
dium. In this sense, it was found that two miRs of miR669 family
(miR669a and miR669q) inhibit skeletal myogenesis in postnatal
cardiac progenitors by suppressing MyoD expression. Notably,
miR669a expression is reduced in cardiac progenitors isolated
from patients with cardiomyopathies due to myocardial infarction
or pathological LV-hypertrophy [72]. In this context, it appears to
be important to determinate miR networks regulated by Pitx2c in
adult myocardium and their putative actions on MRF expression
in the failing heart.
In the classical muscle molecular context, expression of the
MRFs is sensitive to Pitx2 gene dose. It could be foreseeable, for
this reason, that Pitx2c upregulation in the failing myocardium in
response to different pathological stimuli could contribute to MRF
expression and thus impaired cardiac function. Our results provide
previously unrecognized evidence that Pitx2c is reactivated in
postnatal/adult heart at HF that in turn is associated with
modulation of Myf5 expression in failing myocardium. These
findings emphasize the particular importance for future studies to
define the Pitx2 signalling pathways in principal cell types
(cardiomyocytes, fibroblasts, smooth muscle and vascular endo-
thelium cells) of postnatal myocardium.
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Figure S1 Representative qRT-PCR amplification plots for Pitx2c
transcripts in the piglet left ventricle. A - Newborn (NB, green)
versus 30-day-old (30 d, blue) normal piglets. B - PBS-injected
(PBS, blue) versus Dox-injected (Dox, red) 30-day-old animals.
Rpl19 - internal standard levels. Arrows - threshold cycle (CT). FT -
fluorescent threshold. RFU - relative fluorescent units. Under
experimental conditions used, each primer pair yielded a single peak
of dissociation on the melting curve (C) and a single band with the
expected size on PAGE gel post-stained with SYBR Green I (D).
(TIF)
Figure S2 Representative qRT-PCR amplification plots for
Myf5 and Myog transcripts in the left ventricle of PBS- versus Dox-
injected piglets. A - PBS-injected (PBS, blue) versus Dox-injected
(Dox, red) 30-day-old animals. Rpl19 - internal standard levels.
Arrows - threshold cycle (CT). FT - fluorescent threshold. RFU -
relative fluorescent units. Under experimental conditions used,
each primer pair yielded a single band with the expected size on
PAGE gel post-stained with SYBR Green I (B).
(TIF)
Figure S3 Expression of Myog, Foxj1 and Pax3 genes in Pitx2c-
transfected HL-1 and Sol8 cells. Overall relative levels of Myog,
Foxj1 and Pax3 transcripts in HL-1 and Sol8 cells transfected with
V5-tagged Pitx2c vector at different doses (100-400 ng). CT –
empty-vector transfected cells. Shown are results of qRT-PCR
analysis. Data from six replicates of each transfection were pooled
and averaged. *p#0.05.
(TIF)
Table S1 Baseline characteristics of neonatal piglets injected
with Dox or PBS three weeks after injections.
(DOCX)
Table S2 Patient characteristics for samples employed qRT-
PCR and Western blot analyses.
(DOCX)
Table S3 Primers used in this study.
(DOCX)
Table S4 Selective data set derived from the microarray
database.
(DOCX)
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